Lexeo Therapeutics (LXEO) Announces $80M Equity Financing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- Fed’s Warsh says central bank won’t tolerate high inflation
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- Goldman Sachs Upgrades NIO (NIO) to Buy
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
Lexeo Therapeutics (LXEO) PT Lowered to $10 at Leerink Partners
May 27, 2025 1:08 PM EDTLeerink Partners analyst Mani Foroohar lowered the price target on Lexeo Therapeutics (NASDAQ: LXEO) to $10.00 (from $16.00) while maintaining a Outperform rating.
The analyst comments "Bottom Line: This morning LXEO announced a private placement agreement with a group of institutional and healthcare accredited investors for... More
